Introduction
Over the last 30 years, genetics has enhanced our understanding and management of liver disease ( Table 1 ). The fundamental technologies available for genetic analysis encompass positional cloning of unknown disease genes, simple gene tests for known single nucleotide variants (SNV), genome-wide association studies (GWAS) that compare genotype frequencies across the whole genome between cases and controls to identify unknown genetic risk factors, and next-generation sequencing (NGS) of selected genes, all exons, or the whole genome in individual patients.
To illustrate the developments and opportunities of these genetic methods and technologies, we here pose and address five key questions that should help students, researchers, and health care professionals to understand the strides in the genetics of liver disease. Our answers cover both historical aspects and indicate how the advances in our understanding have led to a rapidly developing framework for diagnostic and therapeutic strategies. Rather than a comprehensive representation of the complete genetics of liver disease (for which comprehensive reviews can be found [41] ), we aim to present the reader with key examples of the current state of the field and our associated reflections. We focus on germline mutations and deliberately omit the utility of genomics in the management of hepatocellular carcinoma and cholangiocarcinoma, which is also covered elsewhere [42] and in this special issue.
by linkage disequilibrium and haplotype analysis in more than 100 families [8] . Functional studies demonstrated that it encodes a P-type ATPase gene with metal binding regions similar to those found in prokaryotic heavy metal transporters [9] . Building on this discovery, subsequent studies were able to determine vast aspects of previously unknown aspects of copper transport and the pathophysiology of Wilson disease [43] . Using a similar strategy three years later, the HFE gene in the extended major histocompatibility complex (MHC) was shown to be mutated in patients with autosomal-recessive haemochromatosis [10] . Furthermore, additional types of non-HFE hereditary haemochromatosis were subsequently described, linked to mutations in the ferroportin gene (SLC40A1) [17, 18] , the transferrin receptor 2 gene (TFR2) [19] , the hepcidin gene (HAMP) [20] and the hemojuvelin gene (HJV) [21] , respectively. These genetic discoveries jointly paved the way for the full characterization of hepatic iron metabolism and its regulators [44] , allowing for dissection of mechanisms responsible for the development of liver disease in the presence of detected mutations.
The mutation profile of disease genes varies. Hereditary haemochromatosis is most often caused by a predominant founder mutation (p.C282Y) which accounts for approximately 95% of patients [45] . Wilson disease shows a different genetic profile, with extensive allelic heterogeneity with more than 500 mutations described in the ATP7B gene to date. For this reason, genetic testing in haemochromatosis is undertaken via targeted genotyping of the predominant variants (always starting with p.C282Y), whereas in Wilson disease there is a need for gene sequencing and variant analysis to obtain genetic support for the diagnosis.
The first GWAS in hepatobiliary diseases was performed for gallstone disease and confirmed the candidacy of the hepatobiliary cholesterol transporter ABCG5/G8 as a major susceptibility gene for gallstones worldwide, with p.D19H representing the likely causal single nucleotide polymorphism (SNP) [22, 46] . Other rare loss-of-function SNVs in this transporter had been identified previously, in individual patients, to underlie the monogenic disease sitosterolemia, which is characterized by unrestricted intestinal absorption of both cholesterol and phytosterols such as sitosterol [47] . The adjacent, oppositely oriented ABCG5/G8 genes encode two ATP-binding cassette (ABC) hemitransporters that are localized in the apical membranes of enterocytes and hepatocytes. The case also illustrates a Table 1 . Present day technologies involved in the detection of disease relevant genetic variation. These genomic technologies are principally deriving from a variety of sequencing techniques (targeting genes, the coding regions of the genome [exome] or the whole genome) and microarrays for genome-wide single nucleotide or copy number variant detection. Cost (price) and the availability of relevant bioinformatic tools also need considerations in making the ideal selection of method for investigating any observed trait. [46, 48, 49] . GWAS for autoimmune liver diseases have led to the detection of several dozen risk genes in primary biliary cirrhosis (PBC) [25] , primary sclerosing cholangitis (PSC) [32, 50] and recently, autoimmune hepatitis (AIH) [37] . With few exceptions, the detected risk loci overlap with those of other autoimmune and immune-mediated diseases (Fig. 2) [51] [52] [53] . This means that the majority of the genetic risk factors for these phenotypes involves an increasing susceptibility to autoimmunity rather than liver affections per se. A large fraction of the risk loci and the strong MHC associations found in both PBC, PSC, and AIH point to the pathophysiological importance of adaptive immune responses [46] . The overall genetic contribution to disease susceptibility in PBC, PSC, and AIH is relatively low, with the current risk gene pool representing less than 10% of the overall disease liability [51, 52] . Larger studies will increase this fraction, but more than 50% of the susceptibility to these diseases is still likely to be of an environmental origin.
Mendelian diseases
Individual whole-exome sequencing (WES) has been successfully used to identify unknown genetic variants for inherited diseases or conditions of indeterminate aetiology such Table 2 . Four decades of genetic discoveries in liver diseases. The table lists landmark articles on the genetic susceptibility to liver diseases. The listing is not comprehensive, but serves to show the development of the field over the timespan of the last 40 years. The attention of the field has shifted from the detection of the major histocompatibility complex (MHC) associations in autoimmune liver diseases via the elucidation of the genetics of Mendelian phenotypes to the broader dissection of the genetics of complex liver diseases by genome-wide association studies (GWAS).
Year
Landmark MHC associations in hepatitis B vaccine response (GWAS) [40] as acute liver failure in children [54] . Recently this has been illustrated in two families with unsuspected mitochondrial hepatopathies, where WES of germline DNA indicated homozygous mutations in MPV17 and SERAC1 as causative in paediatric cases of acute liver failure [55] . In fact, liver disease-targeted re-sequencing of genes has been implemented in several liver centres and we believe that it ultimately will be fully integrated into care and get a firm place in the diagnostic evaluation of patients with unexplained liver disease, in particular in the setting of a strong family history of similar afflictions. Due to the massive amounts of data being generated, establishing the pathophysiological connection for detected variants within a clinically relevant time frame remains a major challenge.
Is genetics helpful for the definition of liver diseases and disease subtypes?
Fifty years ago, Byler disease was first described in an Amish kindred [56] . The same disorder in non-Amish populations was termed Byler syndrome, which represented a heterogeneous group of autosomal-recessive liver diseases characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease often before adulthood. In the past two decades basic research teams identified and cloned hepatobiliary transport proteins that are involved in the apical uptake and canalicular secretion of bile acids as well as other endo-and xenobiotics (Fig. 3 ) [57, 58] . The landmark study by Smit et al. [59] demonstrated that homozygous disruption of the murine Mdr2 P-glycoprotein gene, now known as Abcb4, leads to a complete absence of phosphatidylcholine from bile and chronic cholangiopathy. Massive gene amplification and rearrangements also cause hepatocellular cancer in this model [60] . Studies in humans demonstrated that the phenotypic consequences of mutations of the orthologous human gene MDR3/ ABCB4 range from neonatal cholestasis to progressive familial intrahepatic cholestasis (PFIC) and cirrhosis in adults [16, 61] ; they can also result in intrahepatic cholestasis of pregnancy (ICP) [62] as well as intrahepatic and gallbladder cholesterol cholelithiasis, termed low phospholipid-associated cholelithiasis (LPAC) syndrome [63, 64] . The related gene ABCB11 encodes the bile salt export pump (BSEP) and was shown to be mutated in consanguineous families with PFIC but generally low serum c-glutamyl transferase activities [15, 65] . In contrast, patients with Byler disease and others were shown to carry mutations in the ATP8B1 (FIC1) gene [14, 66] which encodes a P-type ATPase that flips phosphatidylserine from the outer to the inner leaflet of the hepatocanalicular membrane, thereby maintaining membrane integrity [67] . Studies comparing the phenotypic presentation and progression between BSEP and FIC1 deficiencies [68, 69] reported that the former patients were more likely to develop neonatal cholestasis and manifested more severe hepatobiliary disease (as indicated by higher serum ALT activities and bile salt show a similar genetic architecture, where a strong association with genes in the major histocompatibility complex (MHC, plotted in red) is the defining feature. Plots derived from data in reference [52] ; the X axis shows chromosomal location, the Y axis shows association statistic for investigated variants (individual dots).
concentrations) as well as cholelithiasis and hepatocellular carcinoma [60, 70] , while the latter showed greater evidence of extrahepatic manifestations (malabsorption, pancreatitis, pneumonia, hearing loss). Most recently a fourth PFIC gene has been described. Mutations in TJP2, encoding tight junction protein 2 (or zona occludens 2), were shown to lead to early onset liver disease [38] . In fact, although all four genes were found to underlie PFIC, each has now been shown to be responsible for spectra with severe and mild phenotypes [22, 66, [71] [72] [73] . Genetic studies have also clarified the pathophysiology of Dubin-Johnson and Rotor syndrome, which are due to mutations of hepatocellular bilirubin transporter genes: mutations of the human canalicular multispecific organic anion transporter gene (now termed ABCC2) underlie Dubin-Johnson syndrome [11] , whereas combined deficiency of the basolateral organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 results in Rotor syndrome by interrupting conjugated bilirubin uptake into the liver [36] . In contrast, mutations in the promoter or exons of the bilirubin conjugating enzyme UGT1A1 underlie hereditary unconjugated hyperbilirubinaemia, with the frequent and benign Gilbert-Meulengracht syndrome being due to a common promoter mutation; more severe mutations cause Crigler-Najjar syndrome in childhood. Unconjugated hyperbilirubinaemia is a known risk factor for gallstone disease, explaining the robust genetic association of the Gilbert-Meulengracht variant and cholelithiasis [74, 75] .
In 1997, Oda et al. [76] and Li et al. [77] demonstrated that another hereditary cholestatic liver disease, Alagille syndrome, is caused by mutations in the human homolog of Jagged-1 (JAG1), which encodes a ligand in the Notch signalling pathway. Alagille syndrome is a rare autosomal-dominant disease with patients showing not only paucity of intrahepatic bile ducts, but characteristic dysmorphic facies and cardiac anomalies, notably peripheral pulmonary stenosis, along with posterior embryotoxon and notched or butterfly vertebrae as well as failure to thrive. In less than 1% of patients, the disease is caused by NOTCH2 mutations [12, 13] , and the phenotypes are now known to be modified by other genes such as thrombospondin 2 [78] .
How might genetics contribute to the classification of liver diseases?
Usually fatty liver disease is attributed to alcohol or metabolic stress, resulting in the terms alcoholic steatohepatitis (ASH) or non-alcoholic steatohepatitis (NASH) [79] . However, ASH may present as acute alcoholic hepatitis or chronic steatohepatitis, and both alcohol and environmental factors (over-nutrition, physical inactivity) can contribute to liver disease. In addition, chemotherapy and other drugs might also cause steatohepatitis. Interestingly, only a subgroup of patients (10-20%) who drink alcohol and/or are overweight develop severe steatohepatitis, advanced fibrosis, and cirrhosis. Since 2008, GWAS-based studies have led to the identification of a major genetic determinant of fatty liver and steatohepatitis as well as progression to fibrosis, cirrhosis, and hepatocellular cancer. Romeo et al. [23] identified the amino acid substitution p.I148M of the lipid droplet-associated trigylceride lipase PNPLA3 (also termed adiponutrin) to confer susceptibility to non-alcoholic fatty liver disease. It appears also to be the major genetic risk factor aggravating alcoholic liver disease [31, 80] . This SNP is highly prevalent in European populations (risk allele frequency 21-28%) and confers a 3-fold risk for liver disease and NASH as well as a 12-fold risk for hepatocellular cancer in comparison to healthy controls [81] . The effect is modified by other genetic risk factors such as TM6SF2 p.E167K [82] but the population-attributable risk for fatty liver disease is highest for PNPLA3 p.I148M [81] . Therefore, we have proposed to use this novel genetic information to define a group of patients with fatty liver disease in whom the susceptibility gene PNPLA3 appears to be a major driver of disease progression, often in combination with ethanol and Western diet but also without, hence the suggested name PNPLA3-associated steatohepatitis (''PASH'') [83] . Although the PNPLA3 risk genotypes confers a high risk of NASH, the patients appear to be sensitive to the beneficial effects of lifestyle modification and dietary intervention should be encouraged to do so [84, 85] .
Common, conserved, aetiopathogenic pathways have been proposed across diseases, often related to failed resolution of responses to infections or stress and damage caused by the patient's immune system [86] . Recently a new cytokine-based taxonomy has been proposed for chronic inflammatory diseases, comprising tumour necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-17, and IL-23 associated diseases, which are characterized by inflammation in different organs such as gut, skin, joints and brain [87] . Preclinical studies and randomised controlled trials with targeted cytokine intervention in humans indicate the existence of a cytokine hierarchy that was used to define these novel disease groups. For example, IL-1 is predominantly involved when inflammasome activation is the dominant mechanism of inflammation, a situation that arises in gout and rare genetic autoinflammatory syndromes such as cryopyrin-associated periodic syndrome and familial Mediterranean fever. Hence, these disorders might be grouped together as IL-1-associated diseases. The fact that the accumulation of metabolic substrates such as urate, cholesterol, ceramide, and glucose can trigger the inflammasome provides the rationale for current therapeutic trials targeting IL-1 in metabolic liver diseases such as fatty liver disease and alcoholic hepatitis. The excessive pleiotropy of autoimmune risk variants provides another example of the imperfect relationship between traditional disease classifications on one side and molecular entities on the other. For autoimmune liver diseases, there are shared features (e.g. SH2B3 variants associating with PBC, PSC and AIH) as well as pathways predominantly associating more on either side of the spectrum (e.g. IL-2-related associations in PSC and IL-12-related associations in PBC) [53] . The importance of these observations as for clinical implementation is still not clear and it is important to acknowledge that phenomenology by means of clinical manifestations (e.g. sclerosing cholangitis) or traditional biochemistry (including autoantibodies) may still represent key biology upon which these apparently diverse associations converge. In Crohn's disease, several susceptibility genes (ATG16L1, NOD2, and IRGM) appear to involve Paneth cell dysfunction as a common denominator for ileal disease affection [88] , exemplifying how the clinical features may still be as valid a representation of key pathophysiology as a gene based classification. As such, data on genetic background and genetic risk factors are likely never to replace disease definitions by medical history and clinical investigations, but may provide another layer of information with a strong potential to refine patient management.
Does genetics affect the treatment of liver disease?
GWAS studies have led to the identification of variants in the IL28B gene encoding interferon (IFN)-k3 that are associated with response to antiviral IFN-based therapy in patients with chronic hepatitis C virus (HCV) infection [28] . Additional studies showed that these polymorphisms are linked with a diplotype of the previously unknown IFN-k4 (IL29) [89] that is induced by HCV and leads to an IFN-stimulated gene expression; a two-base pair insertion or the mutation p.P70S results in loss or reduced activity of IFN-k4, respectively [90, 91] . Of note, the mechanisms involving the IFN-k regulatory axis are not HCV-specific but also determine the outcome of infections with other viruses such as herpes simplex virus type 1 (HSV-1) infection causing vesicular oral and skin lesions, keratitis, or encephalitis [92] . This opens new insights and suggests integrative studies investigating the interaction between the innate immune response, including IFN-k4, and T cells [93] . In light of the new potent direct antiviral agents, the clinical relevance of IL28B and IL29 gene variation has diminished, but it also determines spontaneous clearance of HCV infection [29, 94] . Of note, the gene variants are also associated with the severity of viral hepatitis, even with some contrasting findings [95] , highlighting that the effects of gene polymorphisms can be pleiotropic, increasing the complexity of clinical phenotype, genetic background, and environmental factors [96] . Along the same line, variants of the NASH risk factors PNPLA3 and TM6SF2 have also been shown to modulate cardiovascular risk [97, 98] .
Drug-induced liver injury (DILI) represents a clinically diverse spectrum. Hyman J. Zimmerman discriminated direct and idiosyncratic hepatotoxicity [99] . Whereas direct hepatotoxic drugs lead to dose-related liver injury that is reproducible in animal models, idiosyncratic liver injury shows an unpredictable outcome and is rare. The clinical manifestation of idiosyncratic DILI is acute hepatitis, and to date the diagnosis has been made by exclusion [100] . Idiosyncratic DILI cases are most often caused by antibiotics and generic drugs that have been approved decades ago. In terms of aetiology, DILI is not a single, uncommon disease but rather many, rare diseases converging on a similar presentation of immune-mediated liver injury. A GWAS for a common type of DILI caused by amoxicillin-clavulanate exposure showed the strongest finding in the MHC region, with signals localizing to human leukocyte antigen (HLA) class I and II genes. Although the respective HLA genotypes (HLA-A*02:01 and DQB1*06:02) have limited utility as predictive biomarkers because of low positive-predictive values, they can post hoc serve to assess causality in individual severe cases. Furthermore, the MHC associations point to the involvement of adaptive immunity, likely representing immune reactions to the drug itself, to drug metabolites, or to drug-generated neoantigens (protein adducts), any of which can trigger immunity in otherwise susceptible individuals. Such mechanisms might even be amendable to early treatment with steroids or other types of immunosuppression [101, 102] . To date, additional GWAS have indicated only a limited contribution of common genetic variants outside of the MHC to risk of DILI [103] .
What are the future hurdles and perspectives for translation of genetic research into clinics?
The best strategy for the transformation of the large number of genetic findings into novel therapeutic opportunities for complex liver diseases is not known. Almost 40 years after the discovery of the gene defect in cystic fibrosis [4] , genetic information provides information on the future disease course of individual patients, and variant-specific treatment is being deployed [104] . In PBC, an attempt was made to target the IL-12-related genetic findings by ustekinumab, a monoclonal antibody which targets the p40 subunit of IL-12 and IL-23. The study was terminated due to lack of efficacy (https://clinicaltrials.gov/ct2/show/NCT01389973) and serves to exemplify the point that genetic findings do not necessarily identify therapeutic targets. It is also clear that for the complex phenotypes, genetic findings are also not useful for disease prediction (genetic testing) (Fig. 4) [105, 106] . Both these aspects pertain to the lack of knowledge on interacting environmental (and other genetic) factors and the genuine function of the relevant gene products. In our opinion, the main purpose of genetics in complex phenotypes is to specify experimental research into disease pathophysiology (''pathway detection''). A challenge in forming relevant hypotheses for experimental and translational research following the application of GWAS is that most of the research into the relevant biology has been performed without the prior knowledge of the liver disease associations. Surprising and novel insights are likely to arise from correctly designed experiments on relevant models and human material, exemplified by the unravelling of IL-29 in HCV clearance [89] . These efforts are now urgently needed and will be the source of genuine clinical relevance and therapeutic applications -which so far are lacking for the gene findings per se. Evident from the above discussions, for monogenic and even oligogenic liver diseases, genetic testing is already relevant. Here, the obstacles to clinical implementation are that of access to technology and associated expertise. WES has now been used extensively, and successfully, for research. Whole-genome sequencing (WGS) has advantages and disadvantages in comparison to WES. There is complete genomic coverage, sample preparation is easier, and there is less bias in the generated sequence [107] . Yield, in terms of a conclusive diagnosis is therefore higher [108] . The costs of WGS are decreasing rapidly, but major hurdles to widespread use of either technique for routine diagnostics remains in the interpretation of data. A number of commercial and mainly research-oriented software packages are now available, but none are perfect and there is no integration with the regular patient information systems. The most critical issue remains however the huge number of variants found in each individual. Within these variants lie not only the ''cause'' of Mendelian diseases, but, as discussed above, disease-modifiers and predictors of treatment response. Since disease severity varies even for ''classic'' monogenic liver diseases (Table 1) , it is difficult to tell the difference between a susceptibility allele and a disease modifier, and ultimately every disease is more or less complex (Fig. 4) . We simply do not yet have the knowledge and tools to implement most of the new data in clinical practice. The only way we will be able to approach this information, and thereby get closer to a vision of ''personalized medicine'', is through large cohort studies incorporating detailed clinical and molecular phenotyping alongside the WGS data. Such efforts are needed now more than ever.
